TNGX Key Statistics, Chart & Performance
The current stock price of TNGX is 11.055 USD. In the past month the price increased by 21.27%. In the past year, price increased by 278.12%.
TNGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About TNGX
Company Profile
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Company Info
TANGO THERAPEUTICS INC
201 Brookline Avenue, Suite 901
Boston MASSACHUSETTS US
CEO: Aaron I. Davis
Employees: 155
Phone: 18573204900
TANGO THERAPEUTICS INC / TNGX FAQ
What does TANGO THERAPEUTICS INC do?
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
What is the stock price of TANGO THERAPEUTICS INC today?
The current stock price of TNGX is 11.055 USD. The price decreased by -6.23% in the last trading session.
Does TNGX stock pay dividends?
TNGX does not pay a dividend.
How is the ChartMill rating for TANGO THERAPEUTICS INC?
TNGX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does TANGO THERAPEUTICS INC belong to?
TANGO THERAPEUTICS INC (TNGX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for TANGO THERAPEUTICS INC?
TANGO THERAPEUTICS INC (TNGX) has a market capitalization of 1.49B USD. This makes TNGX a Small Cap stock.
What is the Short Interest ratio of TANGO THERAPEUTICS INC (TNGX) stock?
The outstanding short interest for TANGO THERAPEUTICS INC (TNGX) is 26.23% of its float.
TNGX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TNGX. When comparing the yearly performance of all stocks, TNGX is one of the better performing stocks in the market, outperforming 98.71% of all stocks.
TNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TNGX. TNGX has a great financial health rating, but its profitability evaluates not so good.
TNGX Financial Highlights
Over the last trailing twelve months TNGX reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 22.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.83% | ||
| ROE | -62.81% | ||
| Debt/Equity | 0 |
TNGX Forecast & Estimates
15 analysts have analysed TNGX and the average price target is 13.52 USD. This implies a price increase of 22.25% is expected in the next year compared to the current price of 11.055.
For the next year, analysts expect an EPS growth of 24.88% and a revenue growth 37.77% for TNGX